Key result
Intravenous and intraperitoneal magnesium sulfate (30 mg/kg) significantly reduced postoperative pain scores at 4 hours (P<0.001) and analgesic consumption (P=0.001) compared to saline in LSG.
Why the study?
Hemodynamic changes to pneumoperitoneum and postoperative pain can be detrimental in obese patients, but the efficacy of IV versus IP magnesium sulphate in attenuating these effects was unclear.
Does intravenous or intraperitoneal magnesium sulfate reduce hemodynamic stress and postoperative pain in obese patients undergoing laparoscopic sleeve gastrectomy?
Population
120 patients scheduled for laparoscopic sleeve gastrectomy
Comparison
IV MgSo4 vs IP MgSo4 vs IV and IP saline control
Design
Prospective randomized study
Authors
Loading...
IV/IP magnesium attenuates pneumoperitoneum response and cuts opioid use in obese LSG; extends RCT evidence for adjunctive use in bariatric laparoscopy.
RCT (n=120)
randomized
Does intravenous or intraperitoneal magnesium sulfate reduce hemodynamic stress and postoperative pain in obese patients undergoing laparoscopic sleeve gastrectomy?
p-value: p=<0.001
Both intravenous and intraperitoneal magnesium sulfate attenuate hemodynamic stress and reduce postoperative pain and opioid consumption in obese patients undergoing laparoscopic sleeve gastrectomy.
Mourad et al. (2019) conducted an RCT in obesity undergoing laparoscopic sleeve gastrectomy (n=120). Magnesium sulfate (MgSo4) vs. IV and IP saline was evaluated on mean arterial pressure, heart rate, postoperative pain score, total analgesic consumption, and incidence of adverse events (p=<0.001). Intravenous and intraperitoneal magnesium sulfate (30 mg/kg) significantly reduced postoperative pain scores at 4 hours (P<0.001) and analgesic consumption (P=0.001) compared to saline in LSG.